Lessons learned from a multi‐data source research collaboration: The mirabegron post‐authorization safety study program

Author:

de Vogel Stefan1ORCID,Seeger John D.2ORCID,Arana Alejandro3ORCID,Margulis Andrea V.3ORCID,McQuay Lisa J.4,Perez‐Gutthann Susana3ORCID,Hallas Jesper5ORCID,Kristiansen Nina Sahlertz5,Linder Marie6ORCID,Odsbu Ingvild6,Suehs Brandon7,Xu Yihua7,Uribe Claudia7,Appenteng Kwame8,Robinson Noah Jamie1

Affiliation:

1. Pharmacovigilance Astellas Pharma B.V. Leiden The Netherlands

2. Epidemiology Optum Boston Massachusetts USA

3. Epidemiology RTI Health Solutions Barcelona Spain

4. Epidemiology RTI Health Solutions, Research Triangle Park Durham North Carolina USA

5. Public Health University of Southern Denmark Odense Denmark

6. Medicine, Centre for Pharmacoepidemiology Karolinska Institutet Solna Sweden

7. Health Economics and Outcomes Research Humana Healthcare Research Louisville Kentucky USA

8. Pharmacovigilance Astellas Pharma US Northbrook Illinois USA

Abstract

AbstractBackgroundMany factors contribute to developing and conducting a successful multi‐data source, non‐interventional, post‐authorization safety study (NI‐PASS) for submission to multiple health authorities. Such studies are often large undertakings; evaluating and sharing lessons learned can provide useful insights to others considering similar studies.ObjectivesWe discuss challenges and key methodological and organizational factors that led to the delivery of a successful post‐marketing requirement (PMR)/PASS program investigating the risk of cardiovascular and cancer events among users of mirabegron, an oral medication for the treatment of overactive bladder.ResultsWe provide context and share learnings, including sections on research program collaboration, scientific transparency, organizational approach, mitigation of uncertainty around potential delays, validity of study outcomes, selection of data sources and optimizing patient numbers, choice of comparator groups and enhancing precision of estimates of associations, potential confounding and generalizability of study findings, and interpretation of results.ConclusionsThis large PMR/PASS program was a long‐term commitment from all parties and benefited from an effective coordinating center and extensive scientific interactions across research partners, scientific advisory board, study sponsor, and health authorities, and delivered useful learnings related to the design and organization of multi‐data source NI‐PASS.

Funder

Astellas Pharma US

Publisher

Wiley

Reference23 articles.

1. International Continence Society (ICS).https://www.ics.org/committees/standardisation/terminologydiscussions/overactivebladder. Accessed June 2023

2. U.S. Food and Drug Administration (FDA).https://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202611Orig1s000TOC.cfm. Accessed June 2023

3. European Medicines Agency (EMA).https://www.ema.europa.eu/en/medicines/human/EPAR/betmiga. Accessed June 2023

4. Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study

5. A study of cancer occurrence in users of mirabegron and antimuscarinic treatments for overactive bladder

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3